MENLO PARK, Calif., March 05, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors.As part of its annual review of the leadership structure of... Read more
SAN DIEGO & MENLO PARK, Calif.–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.... Read more
MENLO PARK, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that its Single Molecule, Real-Time (SMRT®) Sequencing technology has been selected by the European research program SOLVE-RD to help reveal the genetic mechanisms responsible for rare genetic... Read more
Wed 17th July 2019 Oxford Nanopore has prevailed once again following the decision yesterday by the European Patent Office (EPO) to revoke a second PacBio European Patent, EP3170904. This decision is consistent with that of an earlier EPO decisionrevoking PacBio European Patent EP3045542, as well as rulings from the ITC and US Court of Appeal that the claims of the... Read more
MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) — While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing... Read more
New system is ideally suited for comprehensive variant detection, large genome de novo assembly, human structural variant characterization, whole transcriptome analysis, and moreMENLO PARK, Calif., April 24, 2019 (GLOBE NEWSWIRE) — Pacific Biosciences of California Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the commercial launch of the... Read more
In a retrospective study, Anthony Nolan Research Institute found SMRT® Sequencing identified superior HLA matches, which are critical in determining successful transplant outcomesMENLO PARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that a retrospective study conducted... Read more
MENLO PARK, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced its participation in this week’s Advances in Genome Biology & Technology (AGBT) General Meeting taking place February 27-March 2 in Marco Island, FL.Several talks by PacBio customers will... Read more
Tue 12th February 2019 – Decision defeats attempts by PacBio to prevent Oxford Nanopore from selling its technology in the US – Oxford Nanopore announces that the US Court of Appeals for the Federal Circuit today upheld the decision of the International Trade Commission (ITC) in favour of Oxford Nanopore. In a complaint previously filed... Read more
January 22, 2019 09:04 AM Pacific Standard Time OXFORD, England–(BUSINESS WIRE)–Today the European Patent Office revoked Pacific Biosciences patent EP3045542 with claims to a single molecule sequencing process wherein two strands of DNA are linked by a connecting nucleic acid. The validity of the patent had been challenged by Oxford Nanopore. The EPO ruled that... Read more